New ASPHO President Hopes to Increase Awareness Around Pediatric Oncology

News
Video

While Maria C. Velez, MD’s, term as president of ASPHO is only 1 year, she is already confident in ASPHO’s strategic plans.

Maria C. Velez, MD, the 2025-2026 president of the American Society of Pediatric Hematology/Oncology (ASPHO), has big plans on how to advance the society and bring more attention to a much-needed specialty.

While her term is only one year, she is very excited to launch the reassessment of the Society’s strategic plan, set to be executed over the next 3 to 5 years. She’ll work with the board members, leadership team, and other members of ASPHO to make sure that it is implemented, to shine a necessary light on the society.

Additionally, she spoke with CancerNetwork® about how the focus of ASPHO has been, among others, on advocacy and being a reputable resource to various outlets. Their collaboration with various oncology groups had added another layer of advocacy and support for the members to, at the same time, benefit the patients and colleagues in the subspecialty.

Outside of ASPHO, Velez is a distinguished professor in the Department of Pediatrics, Division of Hematology/Oncology, and former director of the Pediatric Hematology/Oncology Fellowship at LSU Health Sciences Center School of Medicine-New Orleans. Velez also has several leadership roles at Manning Family Children’s New Orleans.

Transcript:

I’m very excited to launch a reassessment of the society through a strategic plan during my term. My term is a year, and it started in May [2025] and will go through May of 2026. Through this reassessment, we want to learn what issues are of most concern to our members and [community], and how we can dynamically address them. We’ll do this through educational programming, advocacy, and support of the field. The strategic plan combines a 3-to-5-year holistic vision for this specialty with a focus on actionable steps that, together, then help us achieve the shared goals. It’s an ambitious plan, but it’s also critically needed in this environment

Raising awareness of the needs of the pediatric hematology-oncology community is a key priority for ASPHO, so much so that the 2022–2025 strategic plan includes a dedicated goal with specific action steps to address it. Over the past several years, our efforts have expanded to include advocacy initiatives; serving as a trusted resource to the media, policymakers, and health care providers which includes not only our pediatric hematology oncologists, but also other support team colleagues like APPs; building strategic partnerships and coalitions with the American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH), and other stakeholders to speak with a unified voice; and leveraging the expertise of our members to support both patient needs and the advancement of our subspecialty.

Recent Videos
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
Osimertinib/chemotherapy and amivantamab/lazertinib have exhibited an efficacy advantage vs osimertinib in patients with EGFR-mutant NSCLC.